Taking BMS to Court: Will Ex-Celgene’s Shareholders Recover Anything From the Failed CVR?
On Thursday, June 3, Ex-Celgene shareholders filed a case against BMS for missing Breyanzi’s approval deadline and intentionally sinking a multi-billion dollar CVR deal (press release, FiercePharma, Jun 2021). Below, Celltelligence provides insights on potential arguments that ex-Celgene shareholders and BMS could put forward while discussing possible outcome scenarios.
About The Author
The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.
If you receive our email blasts, you already have an account. Log in now
You’ll be able to access the full article from your Celltelligence Library after signing up.